Seebri neohaler 15.6 mcg Inhalation Powder
RxNorm 1721308
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1721308 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: seebri neohaler 15.6 mcg Inhalation Powder.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBD
Semantic Branded Drug (SBD):
Glycopyrrolate 0.0156 mg Inhalation Powder [Seebri]
(Atom ID: 12359466)
SY
Synonym (SY):
Seebri 0.0156 mg Inhalation Powder
(Atom ID: 10788589)
PSN
Prescribable Name (PSN):
Seebri neohaler 15.6 mcg Inhalation Powder
(Atom ID: 10788588)
SY
Synonym (SY):
Seebri Neohaler 15.6 mcg Inhalation Powder
(Atom ID: 10788590)
Patient Education
Glycopyrrolate Oral Inhalation
Glycopyrrolate oral inhalation is used as a long term treatment to control wheezing, shortness of breath, coughing, and chest tightness in patients with chronic obstructive pulmonary disease (COPD; a group of diseases that affect the lungs and airways, that includes chronic bronchitis and emphysema). Glycopyrrolate is in a class of medications called anticholinergics. It works by relaxing the muscles around the airways in your lungs, making it easier to breathe.
[Learn More]
* Please review the disclaimer below.